u/solene_ilunga

Yes. Nobody here is paid and the disclosure page says so in tedious detail, which is the correct level of tedious.

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Pharmacy margins and dispensing fees are regulated nationally, which explains price differences that otherwise look arbitrary.

The scheme cap in Ireland was the single most useful thing I learned in a year of reading this board.

Moderation of individual cases happens in modmail rather than in threads, because a public discussion of one person’s removal is worse for that person than a private one.

Do you have anything in writing from before the payment?

This. Anything urging you to decide today is doing so for its own reasons.

Right, and confirmations are the status. "Sent" means nothing until the chain agrees.

group buys concentrate risk in one person and nobody plans for that

Was in a group buy that went quiet for six weeks. It resolved in the end, but the structure meant I had no visibility and no recourse the whole time.

a shop that will only talk off-platform has told you something

Never name an individual. The sidebar rule exists because the cost of being wrong falls on a person and the benefit of being right falls on nobody in particular.

the Irish scheme cap is the single most useful fact in this board

this place sells nothing and takes nothing from any supplier

Same. Asking which networks are accepted before ordering has saved me twice.

Memo requirements are chain-specific. The chain you are describing does not use one.

a shortage in one member state is not a shortage in all of them

Push back: "nobody has tested them" is a fact about this board, not a fact about the company. Say the first one.

report it here with dates, not adjectives

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

not approved anywhere, which is the single most important fact in this board

Moved from the vendor board.

Adding the cheap insurance — test amount first on anything large.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

In England, specialist weight management services are commissioned locally, so eligibility criteria and waiting times differ by ICB. There is no single national threshold to quote.

screenshot the transaction hash, not the wallet balance

screenshots are not evidence, dates and documents are

A report is useful here when it carries dates, the exact domain, what was requested, what arrived and what did not. Everything else is atmosphere.

cross-border prescription rules exist and they are narrower than people think

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

Argued against the strict evidence rule for a year. Then read a supplier thread on another site and stopped arguing.

Did you send a test amount first?

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.